Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01376011 · ClinicalTrials.gov registry record · Early Phase 1

Modulation of Cerebral Blood Flow Using Quercetin, a Nutritional Supplement

A Early Phase 1 study of Stroke and Problem of Aging, sponsored by Brigham and Women's Hospital.

Completed
Registry status
Early Phase 1
Development phase
106
Enrollment target
1
Study location

NCT01376011 is a Early Phase 1 study of Stroke and Problem of Aging that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 106 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01376011, a Early Phase 1 study of Stroke and Problem of Aging, has completed, sponsored by Brigham and Women's Hospital.

COMPLETED
Registry status
Early Phase 1
Development phase
106 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to find out if quercetin can increase blood levels of hypoxia-inducible transcription factor 1 (HIF-1 protein) and to see if there is a corresponding increase in blood flow to the brain.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT quercetin/placebo

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 106 participants
Start Date 2009-06
Est. Completion 2014-12
Phase Early Phase 1

Sponsor

Brigham and Women's Hospital

937 total trials

What the Registry Record Tells You About NCT01376011

The ClinicalTrials.gov registry entry for NCT01376011 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (99% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Stroke appearing as the primary indexed condition, and to 1 intervention - of which quercetin/placebo is the first listed.

NCT01376011 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01376011 about?

NCT01376011 is a clinical study titled "Modulation of Cerebral Blood Flow Using Quercetin, a Nutritional Supplement". The purpose of this study is to find out if quercetin can increase blood levels of hypoxia-inducible transcription factor 1 (HIF-1 protein) and to see if there is a corresponding increase in blood flow to the brain.

What is the current status of trial NCT01376011?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 106 participants. The study started on 2009-06. Estimated completion is 2014-12.

What conditions does trial NCT01376011 study?

This clinical trial studies the following conditions: Stroke, Problem of Aging.

What interventions are being tested in trial NCT01376011?

The interventions under investigation include: quercetin/placebo (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT01376011?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01376011 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.